Farringdon Capital’s Insmed INSM Stock Holding History

Farringdon Capital’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,332	Closed	-$335K	–	554
2025 Q2	$335K	Buy	+3,332	New	+$255K	0.11%	297

Other funds holding INSM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Farringdon Capital's INSM Position: Q3 2025 in Review

Farringdon Capital sold out of Insmed (INSM) in Q3 2025, closing a stake of 3,332 shares — an estimated $335K sold.

Farringdon Capital first reported a position in INSM in Q2 2025 and held it in 1 quarter. The position peaked at $335K in Q2 2025. 566 funds tracked by Wall St. Rank hold INSM as of Q3 2025.

Farringdon Capital reported no remaining Insmed position as of Q3 2025 after selling out during the quarter.
Farringdon Capital sold 3,332 Insmed shares in Q3 2025, an estimated $335K.
Farringdon Capital first reported a position in Insmed in Q2 2025 and held it in 1 quarter.
Farringdon Capital's Insmed position peaked at $335K in Q2 2025.
566 funds tracked by Wall St. Rank held Insmed as of Q3 2025.

Based on Farringdon Capital's 13F filing for Q3 2025, filed 13 Nov 2025.